Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.
Shanghai's Junshi Biosciences Co. (The Company) recently announced in Biospace, that its product, toripalimab (TUOYI®), combined with bevacizumab as a first-line therapy for hepatocellular carcinoma (HCC), met its endpoints in a…
Continue ReadingToripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma
Ocugen, Inc., a biotechnology company based in Malvern, Pa. recently reported to BioSpace that DSMB gave a favorable review of its Phase ½ ArMaDa clinical study of OCU410. Approximately 10…
Continue ReadingGeographic Atrophy Trials Continue to Make Progress
Individuals who appear to have Long COVID may exhibit a variety of symptoms lasting weeks or even years. The latest estimates are that about 10-20% of people infected with SARS-CoV-2…
A team of scientists from Japan appear to have pioneered a method for reversing synapse damage in an Alzheimer's disease mouse model. Although encouraging, the theory must be tested in…
Continue ReadingJapanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
The idiom ‘third time’s a charm’ may have some significance in this instance. The panel that advises the FDA just voted unanimously in favor of Eli Lilly’s experimental drug, donanemab.…
Continue ReadingFDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease
Professor Michael Goran was referring to research data that was presented at the annual 2023 conference of the Hepatology, Gastroenterology, and Nutrition Society of North America when he stressed that…
Continue ReadingHigher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens
Ruud Dobber, executive VP of biopharmaceuticals at AstraZeneca was quoted in a press release dated saying that type 2 diabetes is on the rise in adolescents and younger children with…
Continue ReadingFarxiga® has been FDA Approved to Treat Children and Adolescents in the U.S. for Type 2 Diabetes
Pfizer has recently paused its Phase III clinical trial that has been assessing the Duchenne muscular dystrophy candidate fordadistrogene movaparvovec. The Phase II DAYLIGHT trial (NCT05429372), enrolled ten boys ages…
Continue ReadingPfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD
One year ago, Jenny Decker age 40 began her journey around the world sailing 3,200 miles to her first stop in Fiji. She reported to Practical Boat Owner that she…
Continue ReadingJenny Decker May Have Charcot-Marie-Tooth Disease, but She is Sailing Around the Globe
This week Neurocrine Biosciences announced the results of its KINECT®-4 Phase 3 study of INGREZZA® capsules. Results of the trial were published in the Journal of Clinical Psychopharmacology. A long-term…
Continue ReadingTardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
Cartesian Therapeutics, Inc., a biotechnology company, recently announced that the FDA has awarded the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, Descartes-08, to treat myasthenia gravis (MG).…
Continue ReadingCartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
Occasionally the acronym NEGU may appear in a social media post. It has been established as a rallying cry and support for people with cancer or other debilitating diseases. It…
Continue ReadingKaren Overpowered Dystonia and Passes the Freedom, Like the Olympic Flame, to her Readers
BioSpace recently published a press release discussing the interim results highlighting a Coya Therapeutics’ study. The study evaluates the safety, tolerability, and biological activity of LD IL-2 in 38 patients…
Continue ReadingEncouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
Jianmin Fang, M.D. the CEO of the biotechnology company RemeGen, recently announced in PRNewswire that the company is continuing its significant progress in its research of Telitacicept (RC18) to treat…
Continue ReadingEnrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy
A major illness can rob some people of their strength and courage, but in other cases it motivates people to get help and, if possible, to help others. 20 years…
Continue ReadingShe Has Cervical Dystonia but Will Wing Walk on a Biplane to Raise Awareness
People who have bipolar depression face a 50% lifetime risk of attempting suicide and a 20% risk of death from suicide. Over seven million people in the U.S. are struggling…
Continue ReadingSuicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone
In a clinical trial conducted by Dr. Talal and his colleagues, the team compared hepatitis C response rates for 602 patients with opioid use disorders. The trials took place…
Continue ReadingTelemedicine Programs Improve Cure Rates for Hepatitis C vs. Specialist Referral
As reported in Biopharma Dive, the FDA’s decision to strengthen its authority involving laboratory developed tests (LDTs) has drawn considerable objections from various healthcare groups. However, the Agency has held…
Continue ReadingNew FDA Regulation on Laboratory Developed Tests Draws Objections from Healthcare Groups
You may not have heard of spinocerebellar ataxia 4 (SCA4). It is rare and it is a devastating movement disease. SCA4 generally begins when a person is 40 or 50,…
Continue ReadingICYMI: After a 25 Year Search, a Doctor Discovers the Cause of Spinocerebellar Ataxia 4
The ALS space looked promising in 2022 after Relyvrio’s approval and a green light for Oalsody in 2023. Then progress stalled a bit in 2024 as a result of Relyvrio…
Continue ReadingAmyotrophic Lateral Sclerosis (ALS): Where Are We Now and Where Are We Going?
Angelman syndrome begins at birth and although symptoms vary, most children exhibit common developmental delays such as: • Infants showing an inability to support their head • Unable to pull…
Continue ReadingA Therapy for Angelman Syndrome Shows Promise, but Adverse Effects Leave Questions
Unexpected but positive results from a late-stage clinical trial were announced by Cerevel Therapeutics and reported in BioPharma Dive last week much to the surprise of AbbVie, the company that…
Continue ReadingAn Investigational Drug to Treat Parkinson’s Produced Surprising Results
On one side of the equation pharmaceutical companies maintain that if drug prices are restricted it will have a negative impact on innovation. Health economists, on the other hand, maintain…
Continue ReadingHis Son’s Diagnosis Inspired a New Biotech Company
An American triathlete, Jon Blais, received a diagnosis of amyotrophic lateral sclerosis (ALS) in 2005 when he was 33 years old. The disease is incurable. Jon was told he had…
Continue ReadingEU Researchers Begin Working on an ALS Treatment and Vaccine
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Sign Up For Our Patient Panel
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.